The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery ...

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

A high-stakes meeting with wide-ranging public health implications again didn’t result in a vote, as members struggled to ...

Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...